Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd

600332.SS · Health Technology · Pharmaceuticals: Major · CN

25,853 employees · gybys.com.cn

About

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd is a leading pharmaceutical company in China that was founded in 1996. The company is headquartered in Guangzhou, the capital of the southern Chinese province of Guangdong. It is listed on the Hong Kong Stock Exchange and employs approximately 11,000 employees. Baiyunshan's business model is based on the production and sale of pharmaceutical products and medical devices. The company operates in various sectors, including the manufacturing of traditional Chinese medicines, Western medicines, pharmaceutical raw materials, medical devices, health products, and cosmetics. Over the years, Baiyunshan has developed an impressive product line focusing on the treatment of various diseases. The company is dedicated to researching and developing new drugs and products to improve the health and well-being of patients. Some of Baiyunshan's most well-known products include Bao Fu Ling, a remedy for skin rashes, and Jigucao, a medication for treating diarrhea. The company has state-of-the-art production facilities in Guangzhou and other parts of China, ensuring the highest quality and standards. Baiyunshan also maintains close collaborations with scientists, researchers, and medical professionals worldwide to ensure that its products align with the latest research findings and technology. Baiyunshan has also established a strong presence internationally and exports to many countries and regions around the world. The company aims to establish its products and services globally and strives to improve access to safe and effective health products worldwide. Overall, Baiyunshan has built its reputation over the years as a leading pharmaceutical company in China dedicated to innovative research and development. Its focus on the highest quality and standards has made a significant contribution to improving the quality of life for millions of people and strengthened its commitment to promoting the health and well-being of the entire community.

Annual results

Reported figures, CNY · revenue up 3.3% in 2025

YearRevenueNet incomeNet marginFree cash flow
202577.4B3.0B3.9%—
202475.0B2.8B3.8%—
202375.5B4.1B5.4%—
202270.8B4.0B5.6%—
202169.0B3.7B5.4%—

Dividends per share

2026 0.45 CNY2025 0.80 CNY2024 1.15 CNY2023 0.73 CNY2022 0.69 CNY

600332.SS in MarketPulse

The live chart with RSI and moving averages, the price, news, signals and price alerts for Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd are inside MarketPulse — currently in private beta.

Company data by Eulerpool. Logos provided by Elbstream. Reported figures, not investment advice.

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (600332.SS) — company profile and financials · MarketPulse